Announced details
Alzheimer’s disease treatment
For the JBC-enabled antibody, increased exposure in the brain was demonstrated while maintaining binding affinity for AβO (specific figures are not disclosed).
A strategic partner with which JCR Pharmaceuticals entered into an agreement in July 2025 to combine its JBC technology with Acumen Pharmaceuticals’ AβO-selective antibody.
A biopharmaceutical company headquartered in Massachusetts, United States. It develops treatments targeting toxic soluble amyloid-beta oligomers (AβO) for the treatment of Alzheimer’s disease.
Not disclosed (Acumen Pharmaceuticals’ headquarters are in Massachusetts, United States)
Up to US$40 million in future development milestone fees and up to US$515 million in sales milestone fees, for a total of up to US$555 million (approximately ¥83.2 billion, based on an exchange rate of ¥150 to the US dollar). Separately, JCR Pharmaceuticals is entitled to receive tiered royalties based on net sales after commercialization. Consideration for the exercise of the option rights will be received, but the amount is not disclosed.
The impact on consolidated results for the fiscal year ending March 2027 has been incorporated into the earnings forecast.
The company does not address Offering price.
International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (presentation of nonclinical data in March 2026); reference: Sadigh-Eteghad et al., Amyloid-beta: a crucial factor in Alzheimer's disease (Med Princ Pract. 2015;24(1):1-10)
| Item | Details |
|---|---|
| Names of Products / Services Covered | J-Brain Cargo® (JBC) technology, sabirnetug（ACU193）, AβO-selective antibody |
| Counterparty | Acumen Pharmaceuticals, Inc.（NASDAQ：ABOS） |
| Counterparty overview | A biopharmaceutical company headquartered in Massachusetts, United States. It develops treatments targeting toxic soluble amyloid-beta oligomers (AβO) for the treatment of Alzheimer’s disease. |
| Relationship with the Company | A strategic partner with which JCR Pharmaceuticals entered into an agreement in July 2025 to combine its JBC technology with Acumen Pharmaceuticals’ AβO-selective antibody. |
| Contract Value | Up to US$40 million in future development milestone fees and up to US$515 million in sales milestone fees, for a total of up to US$555 million (approximately ¥83.2 billion, based on an exchange rate of ¥150 to the US dollar). Separately, JCR Pharmaceuticals is entitled to receive tiered royalties based on net sales after commercialization. Consideration for the exercise of the option rights will be received, but the amount is not disclosed. |
| Contract Date | July 2025 (agreement executed) |
| Launch date | Not disclosed (an IND filing is planned for around mid-2027) |
| Applicable area | Alzheimer’s disease treatment |
| Location | Not disclosed (Acumen Pharmaceuticals’ headquarters are in Massachusetts, United States) |
| Quantitative Effects | For the JBC-enabled antibody, increased exposure in the brain was demonstrated while maintaining binding affinity for AβO (specific figures are not disclosed). |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 has been incorporated into the earnings forecast. |
| Source | International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (presentation of nonclinical data in March 2026); reference: Sadigh-Eteghad et al., Amyloid-beta: a crucial factor in Alzheimer's disease (Med Princ Pract. 2015;24(1):1-10) |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop treatments that combine JCR Pharmaceuticals’ J-Brain Cargo technology with Acumen Pharmaceuticals’ AβO-selective antibody to deliver the antibody to the brain across the blood-brain barrier and inhibit the progression of Alzheimer’s disease pathology.